Dec 16, 2025
Capital Infusion Boosts 4DMedical Limited
4DMedical (ASX:4DX)
had seen its share price fall in October amid profit booking after prior gains and uncertainty over expiring options. The stock then rebounded on funding strength and CTVQ commercialization. The decline reflected typical biotech volatility for small cap medtechs with no negative disclosures evident, though the near complete exercise of deep in the money 4DXOA options raised $22.6M, alongside a $10M Pro Medicus investment and $6M R&D rebate which boosted pro forma cash to $45.5M and extended the runway for U.S. market penetration via Philips. This option event highlighted dilution from prior issuances and noted further 4DXO overhang which likely weighed on sentiment during the dip.